Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q81673391)
Watch
English
Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma
scientific article published on 01 June 2005
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
title
Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
main subject
prostate carcinoma
1 reference
based on heuristic
inferred from title
author name string
Michael J Shulman
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
Elie A Benaim
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
publication date
1 June 2005
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
published in
Cancer
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
volume
103
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
issue
11
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
page(s)
2280-2286
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
cites work
Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natural history of progression after PSA elevation following radical prostatectomy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Complications of advanced prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Percutaneous urinary diversion in patients with hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Supportive care, pain management, and quality of life in advanced prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.21054
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1002/CNCR.21054
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
PubMed ID
15844202
1 reference
stated in
Europe PubMed Central
PubMed ID
15844202
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
